Dr. Dan Brocks, BostonSight Chief Medical Officer, was featured in Ophthalmology Management on January 12, 2026. In this interview, he discusses his role as CMO and the expaning reserach capabilities of BostonSight.
Daniel Brocks, MD: As the CMO, I am fortunate to help in many aspects of patient care, education, and research at BostonSight. My main role is to support patient care in our Needham office, to assist in patient and medical professional education, and to support the clinical research program and our efforts to continue to investigate innovative and novel approaches to treat cornea and ocular surface disease.
We are fortunate to be able to provide each patient with a comprehensive evaluation of their disease state, to create a focused treatment plan, and to afford them the opportunity to participate in breakthrough investigations through our clinical trials program. Patient records are thoroughly evaluated prior to coming to our office, to determine the best approach to their care. While here, each patient has each and every prosthetic replacement of the ocular surface ecosystem (PROSE) device customized for their eye in our on-site ISO certified, FDA registered manufacturing lab. PROSE devices are removable, nickel-sized transparent domes made of gas-permeable plastic that allow oxygen to reach the surface of the eye. They rest on the sclera and vault over the cornea to create a smooth surface over the damaged or diseased cornea. PROSE treatment uses prosthetic devices cleared by the FDA for therapeutic indications.
OM: What do you find the most rewarding about your role as CMO?
Read the entire piece here: Industry Insider. A conversation with BostonSight CMO Dr. Daniel Brocks.